Publication: Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children
dc.contributor.author | Bastard, P. | |
dc.contributor.author | Gervais, A. | |
dc.contributor.author | Taniguchi, M. | |
dc.contributor.author | Saare, L. | |
dc.contributor.author | Särekannu, K. | |
dc.contributor.author | Voyer, T.L. | |
dc.contributor.author | Philippot, Q. | |
dc.contributor.author | Rosain, J. | |
dc.contributor.author | Bizien, L. | |
dc.contributor.author | Asano, T. | |
dc.contributor.author | Garcia-Prat, M. | |
dc.contributor.author | Parra-Martínez, A. | |
dc.contributor.author | Migaud, M. | |
dc.contributor.author | Tsumura, M. | |
dc.contributor.author | Conti, F. | |
dc.contributor.author | Belot, A. | |
dc.contributor.author | Rivière, J.G. | |
dc.contributor.author | Morio, T. | |
dc.contributor.author | Tanaka, J. | |
dc.contributor.author | Javouhey, E. | |
dc.contributor.author | Haerynck, F. | |
dc.contributor.author | Duvlis, S. | |
dc.contributor.author | Özcelik, T. | |
dc.contributor.author | Keles, S. | |
dc.contributor.author | Tandjaoui-Lambiotte ,Y. | |
dc.contributor.author | Escoda, S. | |
dc.contributor.author | Husain, M. | |
dc.contributor.author | Pan-Hammarström, Q. | |
dc.contributor.author | Hammarström, L. | |
dc.contributor.author | Ahlijah, G. | |
dc.contributor.author | Haidar ,A.A. | |
dc.contributor.author | Soudee, C. | |
dc.contributor.author | Arseguel, V. | |
dc.contributor.author | Abolhassani, H. | |
dc.contributor.author | Sahanic, S. | |
dc.contributor.author | Tancevski, I. | |
dc.contributor.author | Nukui ,Y. | |
dc.contributor.author | Hayakawa, S. | |
dc.contributor.author | Chrousos, G.P. | |
dc.contributor.author | Michos, A. | |
dc.contributor.author | Tatsi ,E.B. | |
dc.contributor.author | Filippatos, F. | |
dc.contributor.author | Rodriguez-Palmero, A. | |
dc.contributor.author | Troya, J. | |
dc.contributor.author | Tipu, I. | |
dc.contributor.author | Meyts, I. | |
dc.contributor.author | Roussel, L. | |
dc.contributor.author | Ostrowski, S.R. | |
dc.contributor.author | Schidlowski,L. | |
dc.contributor.author | Prando, C. | |
dc.contributor.author | Condino-Neto, A. | |
dc.contributor.author | Cheikh, N. | |
dc.contributor.author | Bousfiha, A.A. | |
dc.contributor.author | Bakkouri, J.E. | |
dc.contributor.author | Peterson, P. | |
dc.contributor.author | Pujol, A. | |
dc.contributor.author | Lévy, R. | |
dc.contributor.author | Quartier, P. | |
dc.contributor.author | Vinh, D.C. | |
dc.contributor.author | Boisson, B. | |
dc.contributor.author | Béziat, V. | |
dc.contributor.author | Zhang, S.Y. | |
dc.contributor.author | Borghesi, A. | |
dc.contributor.author | Pession, A. | |
dc.contributor.author | Andreakos, E. | |
dc.contributor.author | Marr, N. | |
dc.contributor.author | Mentis, A.F.A. | |
dc.contributor.author | H.mogensen, T. | |
dc.contributor.author | Rodríguez-Gallego, C. | |
dc.contributor.author | Soler-Palacin, P. | |
dc.contributor.author | Colobran, R. | |
dc.contributor.author | Tillmann, V. | |
dc.contributor.author | Neven, B. | |
dc.contributor.author | Trouillet-Assant, S. | |
dc.contributor.author | Brodin, P. | |
dc.contributor.author | Abel, L. | |
dc.contributor.author | Jouanguy, E. | |
dc.contributor.author | Zhang, Q. | |
dc.contributor.author | Martinón-Torres, F. | |
dc.contributor.author | Salas, A. | |
dc.contributor.author | Gómez-Carballa, A. | |
dc.contributor.author | Gonzalez-Granado, L.I. | |
dc.contributor.author | Kisand, K. | |
dc.contributor.author | Okada, S. | |
dc.contributor.author | Puel, A. | |
dc.contributor.author | Cobat, A. | |
dc.contributor.author | Casanova, J.L. | |
dc.contributor.author | Aguilera-Albesa, S. | |
dc.contributor.author | Alkhater, S.A. | |
dc.contributor.author | Alkan, G. | |
dc.contributor.author | Castagnoli, R. | |
dc.contributor.author | Cyrus, C. | |
dc.contributor.author | Bozdemir, S.E. | |
dc.contributor.author | Emiroglu, M. | |
dc.contributor.author | Gulhan, B. | |
dc.contributor.author | Erdeniz, E.H. | |
dc.contributor.author | Hatipoglu, N. | |
dc.contributor.author | Bayhan,G.I. | |
dc.contributor.author | Jabandziev, P. | |
dc.contributor.author | Yuksek, S.K. | |
dc.contributor.buuauthor | TEMEL, ŞEHİME GÜLSÜN | |
dc.contributor.department | Tıp Fakültesi | |
dc.contributor.department | Tıbbi Genetik Ana Bilim Dalı | |
dc.date.accessioned | 2025-05-12T22:39:02Z | |
dc.date.issued | 2024-01-01 | |
dc.description.abstract | We found that 19 (10.4%) of 183 unvaccinated children hospitalized for COVID-19 pneumonia had autoantibodies (auto-Abs) neutralizing type I IFNs (IFN-α2 in 10 patients: IFN-α2 only in three, IFN-α2 plus IFN-ω in five, and IFN-α2, IFN-ω plus IFN-β in two; IFN-ω only in nine patients). Seven children (3.8%) had Abs neutralizing at least 10 ng/ml of one IFN, whereas the other 12 (6.6%) had Abs neutralizing only 100 pg/ml. The auto-Abs neutralized both unglycosylated and glycosylated IFNs. We also detected auto-Abs neutralizing 100 pg/ml IFN-α2 in 4 of 2,267 uninfected children (0.2%) and auto-Abs neutralizing IFN-ω in 45 children (2%). The odds ratios (ORs) for life-threatening COVID-19 pneumonia were, therefore, higher for auto-Abs neutralizing IFN-α2 only (OR [95% CI] = 67.6 [5.7–9,196.6]) than for auto-Abs neutralizing IFN-ω only (OR [95% CI] = 2.6 [1.2–5.3]). ORs were also higher for auto-Abs neutralizing high concentrations (OR [95% CI] = 12.9 [4.6–35.9]) than for those neutralizing low concentrations (OR [95% CI] = 5.5 [3.1–9.6]) of IFN-ω and/or IFN-α2. | |
dc.description.sponsorship | Square Foundation | |
dc.description.sponsorship | Battersea & Bowery Advisory Group | |
dc.description.sponsorship | BGI Genomics | |
dc.description.sponsorship | Institut National de la Santé et de la Recherche Médicale | |
dc.description.sponsorship | ANR AAILC | |
dc.description.sponsorship | Knut och Alice Wallenbergs Stiftelse | |
dc.description.sponsorship | General Atlantic Foundation | |
dc.description.sponsorship | Australasian Centre for Italian Studies | |
dc.description.sponsorship | Fonds de Recherche du Québec - Santé | |
dc.description.sponsorship | Generalitat de Catalunya | |
dc.description.sponsorship | Fondation Bettencourt Schueller | |
dc.description.sponsorship | BI-BACVIR | |
dc.description.sponsorship | Fondation du Souffle | |
dc.description.sponsorship | CovidPhy | |
dc.description.sponsorship | St. Giles Foundation | |
dc.description.sponsorship | Fonds Wetenschappelijk Onderzoek | |
dc.description.sponsorship | Fisher Center for Alzheimer's Research Foundation | |
dc.description.sponsorship | ELIDEK | |
dc.description.sponsorship | European Commission | |
dc.description.sponsorship | Merck Canada | |
dc.description.sponsorship | Agencia Estatal de Investigación | |
dc.description.sponsorship | Rockefeller University | |
dc.description.sponsorship | JPB Foundation | |
dc.description.sponsorship | University of Paris Cité and Imagine Institute | |
dc.description.sponsorship | Stavros Niarchos Foundation Institute for Global Infectious Disease Research | |
dc.description.sponsorship | Glenn Foundation for Medical Research | |
dc.description.sponsorship | Fondation Meyer pour le Développement Culturel et Artistique | |
dc.description.sponsorship | Vetenskapsrådet | |
dc.description.sponsorship | Howard Hughes Medical Institute | |
dc.description.sponsorship | Ministry of Education, Culture, Sports, Science and Technology | |
dc.description.sponsorship | European Research Council See opportunities (opens in new window) HORIZON-HLTL-2021-ID, 101057100 | |
dc.description.sponsorship | OMI-COVI-VAC PI22/00406 | |
dc.description.sponsorship | Ministry of Higher Education, Research and Innovation See opportunities by MoHERI See opportunities (opens in new window) MESRI-COVID-19 | |
dc.description.sponsorship | Fundación Canaria Instituto de Investigación Sanitaria de Canarias | |
dc.description.sponsorship | Fundación Canaria Instituto de Investigación Sanitaria de Canarias FIISC19/43, OA18/017, PIFIISC22/27 | |
dc.description.sponsorship | Operational Program Competitiveness, Entrepreneurship and Innovation T2EDK-02222 | |
dc.identifier.doi | 10.1084/jem.20231353 | |
dc.identifier.issn | 0022-1007 | |
dc.identifier.issue | 2 | |
dc.identifier.scopus | 2-s2.0-85181628485 | |
dc.identifier.uri | https://hdl.handle.net/11452/51420 | |
dc.identifier.volume | 221 | |
dc.indexed.scopus | Scopus | |
dc.language.iso | en | |
dc.publisher | Rockefeller University Press | |
dc.relation.journal | Journal of Experimental Medicine | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | Innate immunity and inflammation | |
dc.subject | Infectious disease and host defense | |
dc.subject | Immunodeficiency | |
dc.subject | COVID-19 | |
dc.subject.scopus | SARS Coronavirus; Interferon Type I; COVID-19 | |
dc.title | Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children | |
dc.type | Article | |
dspace.entity.type | Publication | |
local.contributor.department | Tıp Fakültei/Tıbbi Genetik Ana Bilim Dalı | |
relation.isAuthorOfPublication | f513efaa-a54e-4cfa-840f-28e2fbdc001a | |
relation.isAuthorOfPublication.latestForDiscovery | f513efaa-a54e-4cfa-840f-28e2fbdc001a |